Ranbaxy Wins Approval for First Generic of Novartis’ Diovan

Generic Line
A A
Generics maker Ranbaxy has the green light to launch an exclusive version of Novartis’ blockbuster hypertension drug Diovan, a move that comes nearly two years after the drug lost patent protection.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00